Tesaro joins up with AnaptysBio to develop cancer immunotherapies

|About: Tesaro (TSRO)|By:, SA News Editor

Tesaro (TSRO) has signed a global licensing deal with privately held AnaptysBio for a portfolio of antibodies that could be used to develop cancer immunotherapies.

Tesaro will pay AnaptysBio $17M up front and development costs. For each development project, Tesaro will pay $18M in R&D milestones and $90M related to regulatory progress. AnaptysBio will also receive royalties on any product sales. (PR)